Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06055946
Other study ID # AAG-O-H-2207
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 7, 2023
Est. completion date May 2025

Study information

Verified date March 2024
Source Aesculap AG
Contact Irene Fita Esteban
Phone +34935866200
Email info@bbraun.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this observational study is to show the superiority of the bidirectional barbed suture (Symmcora® Longterm) in terms of time to perform the vesicourethral anastomosis after robot assisted radical prostatectomy compared to the available literature data, without an increase in the complication rate.


Recruitment information / eligibility

Status Recruiting
Enrollment 76
Est. completion date May 2025
Est. primary completion date November 2024
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male patients undergoing an elective robotic assisted radical prostatectomy - Written informed consent - Age = 18years Exclusion Criteria: - Emergency surgery - History of chronic steroid use - Previous prostatic surgery - Previous radiotherapy or brachytherapy - Patients with hypersensitivity or allergy to the suture material. - Participation in another study - Non-compliant patient (dementia etc)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
robotic assisted radical prostatectomy
Adult male patients undergoing elective robotic assisted radical prostatectomy.will be included in the study

Locations

Country Name City State
Spain Hospital General Universitario Gregorio Marañón Madrid
Spain Hospital Universitario Rey Juan Carlos Móstoles Madrid

Sponsors (2)

Lead Sponsor Collaborator
Aesculap AG B.Braun Surgical SA

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Other Assessment of the intraoperative handling of the Symmcora® Long bidirectional Handling of the suture is assessed for every participating surgeon once after inclusion of the last patient. Handling is measured in 16 dimensions + overall impression with five evaluation levels (excellent, very good, good, satisfied, poor) after inclusion of the last patient
Other Assessment of the intraoperative handling of the Symmcora® Mid Unidirectional Handling of the suture is assessed for every participating surgeon once after inclusion of the last patient. Handling is measured in 13 dimensions + overall impression with five evaluation levels (excellent, very good, good, satisfied, poor) after inclusion of the last patient
Primary Time to perform the vesicourethral anastomosis Time to perform the vesicourethral anastomosis using a stopwatch. Time starts when the needle passes the first time the tissue and ends after completion of the anastomosis. Completion of the anastomosis is defined by the last cut of the thread. intraoperatively
Secondary Anastomotic leak rate until 6 months postoperatively Cumulative number of anastomotic leaks up to 6 months after surgery
Secondary Amount of estimate blood loss (EBL) Blood loss is estimated by the amount of intraoperatively needed transfusion intraoperatively
Secondary Transfusion rate Amount of transfused blood, Calculated by multiplication of the number of bags needed and the volume in ml per bag at discharge from hospital (approximately 5-10 days after surgery)
Secondary Urinary retention Urinary retention is an inability to completely empty the bladder at 6 weeks postoperatively
Secondary Urinary fistula rate A urogenital fistula is an abnormal tract that exists between the urinary tract and bladder, ureters, or urethra. A urogenital fistula can occur between any of the organs and structures of the pelvic region. A fistula allows urine to continually exit through and out the urogenital tract. until 6 months postoperatively
Secondary Bladder neck contracture rate Cumulative rate of patients with a complication related to the bladder neck contracture until 6 months postoperatively
Secondary Urinary stone formation rate Cumulative rate of patients with a complication related to urinary stone formation until 6 months postoperatively
Secondary Rate of other complications Cumulative rate of patients with any other complication (infection, embolization, peritonitis, ileus, etc.) until 6 months postoperatively
Secondary Operation consola time Time to perform the intervention from first cut to last cut of the last thread. The time is measured using a stopwatch. intraoperatively
Secondary Time to perform the Rocco stitch Time to perform the modified Rocco stitch: After prostate extirpation, the free edge of the Denonvillier fascia is approximated to the posterior rhabdosphincter/median raphe using a running suture. Then, the Denonvilliers' fascia is fixated to the posterior wall of the bladder, which reduces tension in the anastomosis and provides pelvic support to the bladder neck. The time is measured using a stopwatch. intraoperatively
Secondary Length of postoperative stay Number of days from surgery till patient is discharged from hospital until discharge (approximately 5-10 days postoperatively)
Secondary Catheterization duration Number of days from surgery till catheter was finally removed until first follow-up (6 weeks postoperatively)
Secondary Early continence Days after catheter was finally removed to complete continence 6 weeks postoperatively
Secondary Development of continence by 24-h pad test The 24-hour pad test is used as an objective diagnostic method for the assessment of post prostatectomy stress urinary incontinence. Pads are weighed before and after use and the amount of urine is measured. at 3 months and 6 months postoperatively.
Secondary Development of Erectile Function compared to baseline Erectile Function measured by International Index of Erectile Function (IIEF-5). The International Index of Erectile Function-5 (IIEF-5) is an five-item Index developed to diagnose the presence and severity of erectile dysfunction (ED). The five items are based on ability to identify the presence or absence of ED and on adherence to the National Institute of Health's definition of ED. These items focus on erectile function and intercourse satisfaction. The items are rated on a scale from 1-5 (e.g., 1=Very low to 5=Very high; 1=Almost never/never to 5=Almost always/always; 1=Extremely difficult to 5=Not difficult). The IIEF-5 score is the sum of questions 1 to 5 (Scores range from 5-25). ED was classified into five severity levels, ranging from none (22-25) through severe (5-7). Preoperatively (Baseline), 6 weeks, 3 months and 6 months postoperatively.
Secondary Development of International prostate symptom score (IPSS) compared to baseline The International prostate symptom score (IPSS) questionnaire has seven questions, which are used to evaluate storage and voiding symptoms. The patient is given ?ve options for the ?rst seven questions and each option indicates severity of that symptom. The total score ranges from 0 to 35 and Lower Urinary Tract Symptoms (LUTS) are classi?ed as mild to severe depending on the total score. Patients having a total score =7 are classi?ed as having mild symptoms, scores from 8 to 19 are classi?ed as moderate symptoms, and symptom scores =20 are classi?ed as severe symptoms. Preoperatively (Baseline), 6 weeks, 3 months and 6 months postoperatively.
Secondary Comparison of Prostate Specific Antigen (PSA) at screening and 6 weeks after surgery. PSA response will be measured as the change of serum PSA in ng/mL between preoperative / screening examination and at follow-up 6 weeks after surgery at screening and 6 weeks after surgery.
See also
  Status Clinical Trial Phase
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A